Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
The effects of anti-IL-13 on allergen-induced responses; a Phase II study in subjects with mild atopic asthma - The allergen challenge as a model of allergic asthma for proof-of-concept studies Source: Annual Congress 2008 - Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma Year: 2008
Effect of nasal polivalent bacterial lysate on the clinical course of seasonal allergic rhinitis in children - preliminary study. Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma Year: 2020
Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
Retrospective evaluation of our cohort of patients with chronic estrinsic allergic alveolitis. Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021
A population-based clinical study of allergic and non-allergic asthma Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008
Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Allergic diseases and long-term risk of autoimmune disorders: longitudinal cohort study and cluster analysis Source: Eur Respir J, 54 (5) 1900476; 10.1183/13993003.00476-2019 Year: 2019
The APEX study: A retrospective review of responses of severe allergic asthma patients to omalizumab on continuous or non-continuous oral corticosteroids in UK clinical practice Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
The association between clinical features of asthma and impact of one-year sublingual immunotherapy on immunological system of atopic children Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015
Supression of typ-1 interferon (IFN-a) response in children with allergic asthma is associated with severity of the disease; a prospective cohort study Source: Eur Respir J 2004; 24: Suppl. 48, 161s Year: 2004
Real-world effectiveness of omalizumab in allergic asthma patients with low or high blood eosinophils: A retrospective claims analysis study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Home dampness, molds and allergic rhinitis in childhood: a six-year population-based cohort study Source: Annual Congress 2009 - Environmental factors, susceptibility, asthma and COPD Year: 2009